Английская Википедия:CVL-871
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Cs1 config Шаблон:Multiple issues Шаблон:Infobox drug
CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][3] It is taken via oral administration.[1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy.[1]
See also
- Tavapadon (CVL-751)
References
External links
Шаблон:Dopamine receptor modulators
Шаблон:Nervous-system-drug-stub